ClinicalTrials.gg

Program

suzetrigine

Also written as “Suzetrigine”, “VX-548” and “SUZ”.

Its studies are mostly in Pain · Acute Pain · Neuralgia · Radiculopathy, led by 2 companies.

Furthest: phase 4, since Mar 19, 202527 company-led studies, 3 open or runningNext primary completion: Jan 25, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticals263 open or runningphase 4since Mar 19, 2025Jul 15, 2021Jan 25, 2027phase 3 · NCT06696443
Latigo Biotherapeutics10 open or runningearly phase 1since May 6, 2025May 6, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Jul 15, 2021.

  1. Jan 19, 2023Phase 1 study in PainVertex Pharmaceuticals · NCT05704556 · 38 enrolled · United States
  2. Apr 5, 20232 phase 1 studies in PainVertex Pharmaceuticals · NCT05818852, NCT05851157
  3. Dec 10, 2023Phase 2 study in Painful Lumbosacral RadiculopathyVertex Pharmaceuticals · NCT06176196 · 218 enrolled · United States
  4. Mar 21, 2024Phase 1 study in PainVertex Pharmaceuticals · NCT06336096 · 48 enrolled · United States
  5. May 14, 2024Phase 1 study in PainVertex Pharmaceuticals · NCT06420765 · 92 enrolled · United Kingdom
  6. Sep 30, 2024Phase 3 study in Diabetic Peripheral Neuropathic PainVertex Pharmaceuticals · NCT06628908 · 1,100 planned · United States
  7. Nov 15, 2024Phase 3 study in Diabetic Peripheral Neuropathic PainVertex Pharmaceuticals · NCT06696443 · 455 enrolled · United States
  8. Feb 5, 20252 phase 1 studies in PainVertex Pharmaceuticals · NCT06820307, NCT06834009
  9. Mar 19, 20252 phase 4 studies in Acute PainVertex Pharmaceuticals · NCT06887972, NCT06887959
  10. May 6, 2025Latigo Biotherapeutics's first study: early phase 1 study in Pain DetectionNew to Latigo BiotherapeuticsLatigo Biotherapeutics · NCT06972212 · 20 enrolled · New Zealand
  11. Nov 13, 2025Phase 3 study in Diabetic Peripheral Neuropathic PainVertex Pharmaceuticals · NCT07231419 · 734 planned · United States
  12. Jan 23, 2026Phase 1 study in PainVertex Pharmaceuticals · NCT07378865 · 13 enrolled · United States
  13. Apr 13, 2026Phase 4 study in PainVertex Pharmaceuticals · NCT07538570 · 66 enrolled · United States
  14. Apr 29, 2026Phase 1 study in PainVertex Pharmaceuticals · NCT07570069 · 18 enrolled · United States

Ahead

  1. Jan 25, 2027Primary completion: phase 3 study in Diabetic Peripheral Neuropathic PainVertex Pharmaceuticals · NCT06696443
  2. Apr 6, 2027Primary completion: phase 3 study in Diabetic Peripheral Neuropathic PainVertex Pharmaceuticals · NCT07231419
  3. May 31, 2027Primary completion: phase 3 study in Diabetic Peripheral Neuropathic PainVertex Pharmaceuticals · NCT06628908

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 27 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07570069Pain · United States1CompletedVertex PharmaceuticalsJul 16, 202618
NCT07538570Pain · United States4CompletedVertex PharmaceuticalsOct 12, 202666
NCT07378865Pain · United States1CompletedVertex PharmaceuticalsAug 17, 202613
NCT07231419Diabetic Peripheral Neuropathic Pain · United States3RecruitingVertex PharmaceuticalsApr 6, 2027734
NCT06972212Pain Detection · New ZealandEarly 1CompletedLatigo BiotherapeuticsJun 28, 202520
NCT06887972Acute Pain · United States4CompletedVertex PharmaceuticalsOct 24, 2025100
NCT06887959Acute Pain · United States4CompletedVertex PharmaceuticalsOct 27, 202547
NCT06834009Pain · United States1CompletedVertex PharmaceuticalsApr 24, 202510
NCT06820307Pain · United States1CompletedVertex PharmaceuticalsApr 29, 202550
NCT06696443Diabetic Peripheral Neuropathic Pain · United States3Active, not recruitingVertex PharmaceuticalsJan 25, 2027455
NCT06628908Diabetic Peripheral Neuropathic Pain · United States3RecruitingVertex PharmaceuticalsMay 31, 20271,100
NCT06420765Pain · United Kingdom1CompletedVertex PharmaceuticalsMar 22, 202592
NCT06336096Pain · United States1CompletedVertex PharmaceuticalsJun 19, 202448
NCT06176196Painful Lumbosacral Radiculopathy · United States2CompletedVertex PharmaceuticalsOct 2, 2024218
NCT05851157Pain · United States1CompletedVertex PharmaceuticalsOct 30, 202373
NCT05818852Pain · United States1CompletedVertex PharmaceuticalsJun 12, 202372
NCT05704556Pain · United States1CompletedVertex PharmaceuticalsMar 30, 202438
NCT05661734Pain · United States3CompletedVertex PharmaceuticalsDec 12, 2023258
NCT05660538Diabetic Peripheral Neuropathy · United States2CompletedVertex PharmaceuticalsOct 12, 2023194
NCT05635110Pain · Australia1CompletedVertex PharmaceuticalsJun 8, 202331
NCT05560464Pain · United States1CompletedVertex PharmaceuticalsJul 24, 202336
NCT05558410Acute Pain · United States3CompletedVertex PharmaceuticalsAug 25, 20231,118
NCT05553366Acute Pain · United States3CompletedVertex PharmaceuticalsDec 15, 20231,075
NCT05541471Pain · United States1CompletedVertex PharmaceuticalsApr 16, 202337
NCT05455502Pain · United States1CompletedVertex PharmaceuticalsSep 17, 202224
NCT05034952Acute Pain · United States2CompletedVertex PharmaceuticalsDec 5, 2021303
NCT04977336Acute Pain · United States2CompletedVertex PharmaceuticalsFeb 17, 2022274

How it is read

Names in the registry

  • “Suzetrigine”, 13 entries
  • “VX-548”, 11 entries
  • “SUZ”, 2 entries
  • “suzetrigine 100mg”, 1 entry
  • “Suzetrigine (SUZ)”, 1 entry

Codes read as this program: VX548.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.